Can a simple test predict CAR t success? new study aims to find out.
NCT ID NCT07472972
First seen Mar 26, 2026 · Last updated May 02, 2026 · Updated 3 times
Summary
This study is testing a new way to predict which patients with B-cell lymphoma will respond to CAR T cell therapy. Researchers will combine blood tests, scans, and immune system measurements to create a personalized risk profile. The goal is to see if this tool can be completed successfully for each patient. 50 adults with relapsed or refractory lymphoma who are already scheduled for CAR T therapy will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Universityhospital Zurich, Department of Medical Oncology and Hematology
RECRUITINGZurich, Canton of Zurich, 8091, Switzerland
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.